Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03683680 · ClinicalTrials.gov registry record · NA

Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers

A NA study of Mesothelioma, sponsored by Dana-Farber Cancer Institute.

Recruiting
Registry status
NA
Development phase
240
Enrollment target
1
Study location

NCT03683680 is a NA study of Mesothelioma that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 240 participants, above the 193-participant average among 46 other Mesothelioma trials with a reported enrollment target (24% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03683680, a NA study of Mesothelioma, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status
NA
Development phase
240 participants
Enrollment target
1
Study location

Study Summary

This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.

Conditions Studied

Mesothelioma

Interventions

  • OTHER MPT Test
  • OTHER CLDN15/VIM Test

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2018-10-31
Est. Completion 2030-10-01
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03683680

The ClinicalTrials.gov registry entry for NCT03683680 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 193-participant average among 46 other Mesothelioma trials with a reported enrollment target (24% higher). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which MPT Test is the first listed.

NCT03683680 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03683680 about?

NCT03683680 is a clinical study titled "Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers". This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.

What is the current status of trial NCT03683680?

This trial is currently recruiting. It is a NA study. The enrollment target is 240 participants. The study started on 2018-10-31. Estimated completion is 2030-10-01.

What conditions does trial NCT03683680 study?

This clinical trial studies the following conditions: Mesothelioma.

What interventions are being tested in trial NCT03683680?

The interventions under investigation include: MPT Test (OTHER), CLDN15/VIM Test (OTHER).

Who is sponsoring clinical trial NCT03683680?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03683680 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mesothelioma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Mesothelioma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.